Message Font: Serif | Sans-Serif
No. of Recommendations: 14
hi fellow Fools,

as promised, here my next post regarding Exelixis

GDC-0973, Genetech/Roche's potent, selective MEK1/2 inhibitor, is used in combination with a PI3K inhibitor in the treatment of solid tumors.

Interesting fact: GDC-0973 is also known as XL-518 (originally developped by Exelixis !). See reference here:

At ESMO 2012 there will be a pivotal latebreaker presentation - LBA28 - of a phase-I trial; as this information is embargoed, the results will be available on Saturday, Sep 29, 2012, 9:15 am (Vienna time)the earliest.
I intend to make the conclusion of this latebreaker available to you asap., since I plan to attend this session

It looks like Exelixis has another hot iron in the forge...

take care, marsuculix
(I am a molecular biologist and consultant to Swiss pharmaceutical companies - I will try to dig a hole to my former university colleagues working @ Roche - may be it pays off)
Print the post  


When Life Gives You Lemons
We all have had hardships and made poor decisions. The important thing is how we respond and grow. Read the story of a Fool who started from nothing, and looks to gain everything.
Contact Us
Contact Customer Service and other Fool departments here.
Work for Fools?
Winner of the Washingtonian great places to work, and Glassdoor #1 Company to Work For 2015! Have access to all of TMF's online and email products for FREE, and be paid for your contributions to TMF! Click the link and start your Fool career.